PMID- 16516532
OWN - NLM
STAT- MEDLINE
DCOM- 20060727
LR  - 20071114
IS  - 1359-6101 (Print)
IS  - 1359-6101 (Linking)
VI  - 17
IP  - 3
DP  - 2006 Jun
TI  - Transcriptional anti-angiogenesis therapy of human pancreatic cancer.
PG  - 147-56
AB  - Pancreatic cancer angiogenesis has been attributed to genetic and epigenetic 
      alterations (e.g., oncogene activation and suppressor inactivation) and a chaotic 
      tumor microenvironment (e.g., hypoxia, acidosis, free radical stress and 
      imbalanced growth factor production). Those diverse "upstream signal" factors 
      appear to converge their signaling pathways on limited sets of nuclear 
      transcription factors (e.g., Sp1, Stat3 and NF-kappaB). Aberrant activities of 
      these factors confer a tremendous survival and growth advantage to existing 
      and/or emerging malignant cells through alteration of the expression and 
      functions of their diverse "downstream effector" factors (e.g., VEGF and IL-8). 
      Therefore, targeting a single transcription factor can affect the malignant 
      phenotype more profoundly than just targeting any single upstream signal and/or 
      downstream effector factor.
FAU - Xie, Keping
AU  - Xie K
AD  - Department of Gastrointestinal Medical Oncology, Unit 426, The University of 
      Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, 
      USA. kepxie@mail.mdanderson.org
FAU - Wei, Daoyan
AU  - Wei D
FAU - Huang, Suyun
AU  - Huang S
LA  - eng
GR  - 1P20-CA101936-01-PP4/CA/NCI NIH HHS/United States
GR  - 1R01-CA093829/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20060303
PL  - England
TA  - Cytokine Growth Factor Rev
JT  - Cytokine & growth factor reviews
JID - 9612306
RN  - 0 (Angiogenesis Inducing Agents)
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Angiogenesis Inducing Agents/antagonists & inhibitors/metabolism
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Carcinoma, Pancreatic Ductal/*drug therapy/*genetics
MH  - Humans
MH  - Neovascularization, Pathologic/*drug therapy/genetics
MH  - Pancreatic Neoplasms/blood supply/*drug therapy/genetics
MH  - Signal Transduction
MH  - Transcription Factors/*metabolism
MH  - Transcription, Genetic
RF  - 100
EDAT- 2006/03/07 09:00
MHDA- 2006/07/28 09:00
CRDT- 2006/03/07 09:00
PHST- 2006/03/07 09:00 [pubmed]
PHST- 2006/07/28 09:00 [medline]
PHST- 2006/03/07 09:00 [entrez]
AID - S1359-6101(06)00004-9 [pii]
AID - 10.1016/j.cytogfr.2006.01.002 [doi]
PST - ppublish
SO  - Cytokine Growth Factor Rev. 2006 Jun;17(3):147-56. doi: 
      10.1016/j.cytogfr.2006.01.002. Epub 2006 Mar 3.